Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.
first published: May 15, 2012 04:33 pm
A collection of the most-viewed Moneycontrol videos.
U.S.-Iran War Intensifies; Trump Reveals Next Step, What Will Be His Next Target?
U.S. Gives India 30-Day Waiver To Purchase Russian Oil
Crude Prices Stay High; Talks To Reopen Strait of Hormuz | Trump Tariffs Under Fire | Opening Bell
Live: Nifty snaps 3-day losing streak as markets shake off war jitters | Closing Bell
